Item 8.01 Other Events.

On December 17, 2008, Neurobiological Technologies, Inc. (the "Company") issued a press release announcing that its lead investigational drug, Viprinex™, did not pass an interim futility analysis in a clinical trial evaluating Viprinex for the treatment of acute ischemic stroke. The Company also announced that it has terminated enrollment in the clinical trial and that it will be analyzing the data from the interim analysis to assess whether Viprinex should be developed further. A copy of this press release is filed herewith as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No. Description

99.1 Press Release, dated December 17, 2008